Exclusive / Elon Musk’s Neuralink raises fresh cash at $9B valuation

Neuralink has raised $600 million, valuing the company at $9 billion pre-money, a significant increase from its $3.5 billion valuation in late 2023. This valuation surge follows the successful implantation of Neuralink chips in three patients, including one ALS patient who demonstrated the ability to speak using the device. While more volunteers are receiving implants, commercial release is not yet imminent, as the company continues to focus on critical technology development.

Analysis

Neuralink has secured $600 million in new funding, establishing a pre-money valuation of $9 billion. This represents a substantial increase from its $3.5 billion valuation in late 2023, a surge largely attributed to recent technological milestones, including the successful implantation of its brain-computer interface chips in three patients, one of whom, an ALS patient, demonstrated the ability to communicate using the device. This latest funding round and valuation slightly exceed the previously reported target of $500 million at an $8.5 billion valuation mentioned by Bloomberg in April. While this valuation positions Neuralink as a significant entity in the neurotechnology sector, it remains one of the smaller components of Elon Musk's portfolio, which includes SpaceX, valued at $180 billion in August (and reportedly $350 billion on the secondary market by December 2024), and xAI, which contributed to a combined company value of $113 billion upon merging with X. Despite these advancements and increasing volunteer participation in trials, the MIT Technology Review noted earlier this year that Neuralink’s product is not yet ready for commercial release, underscoring the ongoing intensive research and development phase. Musk's recent statements affirm his deep focus on achieving critical technology rollouts at Neuralink, in parallel with xAI and Tesla, indicating a pivotal period for the company.

Key Decisions for Investors

• The significant valuation uplift for Neuralink, a pre-commercial entity, signals strong private market confidence in the disruptive potential of brain-computer interface technology and Musk-led ventures, indicating high long-term return possibilities but also reflecting substantial embedded future expectations.
• Investors should closely monitor Neuralink's progress towards key milestones such as further successful human trials, regulatory approvals, and clearer timelines for commercialization, as these will be critical de-risking events for a venture in such an advanced and capital-intensive technological field.
• Given Elon Musk's declared intensive focus on Neuralink alongside xAI and Tesla, investors in publicly traded Musk-associated companies, such as Tesla, should consider the potential implications of his resource allocation and executive attention across his diverse and demanding ventures.